Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis c therapy among patients coinfected with hepatitis c and HIV

AIDS Patient Care and STDs

Volumn 28, Issue 10, 2014, Pages 513-516

  Patel, Nimish ^a   Veve, Michael ^a   Nasiri, Mona ^a   Bliss, Steven ^a   McNutt, Louise Anne ^b   Lazariu, Victoria ^b   Miller, Christopher ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c University Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ATAZANAVIR; BOCEPREVIR; CALCIUM CHANNEL BLOCKING AGENT; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEUROLEPTIC AGENT; NEVIRAPINE; PEGINTERFERON ALPHA; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PROLINE; PROTEINASE INHIBITOR;

ADULT; AGED; ANTIVIRAL THERAPY; CONTROLLED STUDY; DRUG CONTRAINDICATION; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROBABILITY; ANALOGS AND DERIVATIVES; CROSS-SECTIONAL STUDY; DRUG INTERACTION; HIV INFECTIONS; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED STATES;

ADULT; COINFECTION; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW YORK; PROBABILITY; PROLINE; PROTEASE INHIBITORS; TREATMENT OUTCOME;

EID: 84907605347     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2014.0149     Document Type: Letter

References (10)

1. Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: Virological, immunologi-cal, and clinical outcomes. J Virol 2009;83:7366-7374.
2. Mandorfer M, Payer BA, Niederecker A, et al. Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. AIDS Patient Care STDs 2014;28:221-227.
3. American Association for the Study of Liver Diseases, Infectious Diseases Society of America and International AIDS Society-USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org (Last accessed May 15, 2014).
4. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31 Suppl 2:61-80.
5. Patel N, Veve M, Bliss S, et al. Prevalence and predictors of important telaprevir drug interactions among patients coinfected with hepatitis C and human immunodeficiency virus. J Pharm Technol 2014:1-9.
6. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003;157:940-943.
7. Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother 2013;47:1429-1439
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Last accessed May 15, 2014).
9. Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastro-enterology 2006;131:478-484.
10. Jonckheere S, Vincent A, Belkhir L, Wilmes D, Vandercam B, Yombi JC. Adherence to screening guidelines for hepatitis C among HIV-positive patients. AIDS Patient Care STDs 2013;27:317-319.